Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “sell” rating restated by equities researchers at Wells Fargo & Co in a report issued on Tuesday.

Other equities research analysts have also recently issued reports about the company. BTIG Research cut Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 target price for the company. in a research note on Friday, February 2nd. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Leerink Swann cut their target price on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating for the company in a research note on Friday, February 9th. Piper Jaffray Companies cut Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 target price for the company. in a research note on Friday, February 9th. Finally, Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Ten research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $21.26.

Shares of Teva Pharmaceutical Industries (TEVA) traded up $1.45 during mid-day trading on Tuesday, hitting $20.78. The company had a trading volume of 45,047,762 shares, compared to its average volume of 20,807,631. The company has a current ratio of 0.86, a quick ratio of 0.66 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $20,930.00, a PE ratio of -1.20, a P/E/G ratio of 1.60 and a beta of 0.59. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the company posted $1.38 earnings per share. The firm’s revenue for the quarter was down 15.9% compared to the same quarter last year. equities research analysts predict that Teva Pharmaceutical Industries will post 2.31 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Nova Scotia increased its holdings in Teva Pharmaceutical Industries by 8.3% in the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock valued at $229,000 after purchasing an additional 528 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Teva Pharmaceutical Industries by 1.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company’s stock valued at $3,755,000 after purchasing an additional 3,100 shares during the period. WealthTrust Axiom LLC increased its holdings in Teva Pharmaceutical Industries by 29.9% in the fourth quarter. WealthTrust Axiom LLC now owns 14,948 shares of the company’s stock valued at $283,000 after purchasing an additional 3,440 shares during the period. Argyle Capital Management Inc. increased its holdings in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Argyle Capital Management Inc. now owns 60,750 shares of the company’s stock valued at $1,151,000 after purchasing an additional 3,598 shares during the period. Finally, Guardian Investment Management increased its holdings in Teva Pharmaceutical Industries by 26.9% in the third quarter. Guardian Investment Management now owns 17,700 shares of the company’s stock valued at $311,000 after purchasing an additional 3,750 shares during the period. Institutional investors and hedge funds own 51.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Earns Sell Rating from Wells Fargo & Co” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/15/teva-pharmaceutical-industries-teva-stock-rating-reaffirmed-by-wells-fargo-co.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.